Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F20%3A00072905" target="_blank" >RIV/00159816:_____/20:00072905 - isvavai.cz</a>
Result on the web
<a href="https://www.mdpi.com/1422-0067/21/7/2435/htm" target="_blank" >https://www.mdpi.com/1422-0067/21/7/2435/htm</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/ijms21072435" target="_blank" >10.3390/ijms21072435</a>

Result language
angličtina
Original language name
Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy
Original language description
Human pluripotent stem cells have the potential to change the way in which human diseases are cured. Clinical-grade human embryonic stem cells and human induced pluripotent stem cells have to be created according to current good manufacturing practices and regulations. Quality and safety must be of the highest importance when humans' lives are at stake. With the rising number of clinical trials, there is a need for a consensus on hPSCs characterization. Here, we summarize mandatory and ' for information only ' characterization methods with release criteria for the establishment of clinical-grade hPSC lines.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology

Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)